Where to Buy Fragment, CJC1295, Ipamorelin: Vendor Comparison & Research Info

This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabled as a drug, food or cosmetic.

Fragment 176-191

Fragment 176-191 is a small section of human growth hormone sequence (hGH) that has been shown in animal models to enhance fat burning and shift metabolism toward the maintenance of lean body mass[1]–[3]. Research also suggests that fragment 176-191 also lacks many of the side effects caused by hGH such as decreased insulin sensitivity, long-bone growth, and edema. That said, the fragment could contribute to the normal physiologic mechanisms that control GH secretion and could therefore positively affect levels of GH according to recent research studies.

CJC-1295

CJC-1295 could counteract the GH effects of fragment 176-191 as it is a synthetic growth hormone releasing hormone and therefore stimulates the release of G[4]. CJC-1295 acts to increase basal and peak levels of GH and has also been shown to increase free plasma levels of GH. Only free GH is biologically active. CJC-1295 can therefore compensate for a normal physiologic response to fragment 176-191. This would allow for the benefits of fragment 176-191 to be realized without having any impact on normal GH secretion.

To further boost GH secretion above basal levels and to particularly affect peak GH secretion, Ipamorelin could be added to the mix. Ipamorelin is a growth hormone secretagogue receptor agonist that has been shown in animal studies to have potent and specific effects on GH secretion while having very limited side effects[5]. Ipamorelin has also been shown to be highly beneficial to bone mineralization and insulin control in animal models[6], [7]. Ipamorelin is a short-acting peptide whereas CJC-1295 is a longer-acting peptide. The former provides rapid onset GH release while the latter acts to raise GH secretion over longer periods and maintain normal physiologic secretion patterns

Scientific Journal Author

Dr. Dominique Bridon holds a Master of Science, Chemical Engineering and Polymer Sciences from Ecole Nationale Supérieure de Chimie and a PhD in Organic Chemistry from the University of Paris XI, ICSN, Orsay, France with Nobel Laureate Sir Derek H. R. Barton as Research Advisor. He completed his Post-Doctoral Research at the University of California, Berkeley. He studied the potential of CJC-1295 as a long lasting GRF analog and also held various leadership positions involving peptide research and technologies at Ipsen, Conjuchem, Redcell, and Abbott Laboratories. Dr. Bridon has served as a Director for Enobia (acquired by Alexion) and Neuronax and as a member of the Scientific Advisory Board of Syntaxin (acquired by Ipsen) and Biosortia. He now brings 30 years of executive and scientific leadership experience to the Epivax Oncology team.

Dr. Dominique Bridon is being referenced as one of the leading scientists involved in the research and development of CJC-1295. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between  peptide Review Hub and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Dr. Dominique Bridon is listed in [10] under the referenced citations.